300 related articles for article (PubMed ID: 16000593)
41. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
[TBL] [Abstract][Full Text] [Related]
42. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.
Luo H; Quan H; Xie C; Xu Y; Fu L; Lou L
Leukemia; 2010 Oct; 24(10):1807-9. PubMed ID: 20703259
[No Abstract] [Full Text] [Related]
43. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
44. Overriding imatinib resistance with a novel ABL kinase inhibitor.
Shah NP; Tran C; Lee FY; Chen P; Norris D; Sawyers CL
Science; 2004 Jul; 305(5682):399-401. PubMed ID: 15256671
[TBL] [Abstract][Full Text] [Related]
45. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors.
Grosso S; Puissant A; Dufies M; Colosetti P; Jacquel A; Lebrigand K; Barbry P; Deckert M; Cassuto JP; Mari B; Auberger P
Mol Cancer Ther; 2009 Jul; 8(7):1924-33. PubMed ID: 19567819
[TBL] [Abstract][Full Text] [Related]
46. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
[TBL] [Abstract][Full Text] [Related]
47. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
[TBL] [Abstract][Full Text] [Related]
48. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J
Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059
[TBL] [Abstract][Full Text] [Related]
49. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
[TBL] [Abstract][Full Text] [Related]
50. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
51. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Corrado C; Flugy AM; Taverna S; Raimondo S; Guggino G; Karmali R; De Leo G; Alessandro R
PLoS One; 2012; 7(8):e42310. PubMed ID: 22879938
[TBL] [Abstract][Full Text] [Related]
52. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
[TBL] [Abstract][Full Text] [Related]
53. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
54. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T; Ashihara E; Kimura S
Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
[TBL] [Abstract][Full Text] [Related]
55. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
56. Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.
Gambacorti-Passerini CB; Rossi F; Verga M; Ruchatz H; Gunby R; Frapolli R; Zucchetti M; Scapozza L; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; D'Incalci M; Corneo G
Blood Cells Mol Dis; 2002; 28(3):361-72. PubMed ID: 12367580
[TBL] [Abstract][Full Text] [Related]
57. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A
Haematologica; 2008 May; 93(5):765-9. PubMed ID: 18367481
[TBL] [Abstract][Full Text] [Related]
58. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
59. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
60. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Giles FJ; Cortes JE; Kantarjian HM
Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]